WC
SPRY icon

Wexford Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Wexford Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-130,313
Closed -$1.05M – 255
2026
Q1 		$1.05M Sell
130,313
-35,000
-21% -$335K 0.15% 59
2025
Q4 		$1.93M Sell
165,313
-2,925
-2% -$28.4K 0.37% 47
2025
Q3 		$1.69M Sell
168,238
-214,317
-56% -$3.08M 0.24% 42
2025
Q2 		$6.68M Sell
382,555
-25,996
-6% -$375K 1.86% 11
2025
Q1 		$5.14M Buy
408,551
+39,054
+11% +$470K 1.34% 17
2024
Q4 		$3.9M Buy
369,497
+121,150
+49% +$1.7M 0.62% 30
2024
Q3 		$3.6M Buy
+248,347
New +$2.95M 0.86% 32

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wexford Capital's SPRY Position: Q2 2026 in Review

Wexford Capital sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 130,313 shares — an estimated $1.05M sold.

Wexford Capital first reported a position in SPRY in Q3 2024 and held it in 7 quarters. The position peaked at $6.68M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Wexford Capital reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Wexford Capital sold 130,313 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Wexford Capital first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Wexford Capital's ARS Pharmaceuticals position peaked at $6.68M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.